Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment.
Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Horiike A, Wada S, Ariyoshi T, Goto S, Otsuka K, Murakami M, Kiuchi Y, Yoshimura K, Hoffman RM, Tsunoda T. Hirasawa Y, et al. Among authors: iriguchi n. Anticancer Res. 2024 Aug;44(8):3397-3407. doi: 10.21873/anticanres.17160. Anticancer Res. 2024. PMID: 39060084
Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary.
Suzuki R, Hamada K, Ohkuma R, Homma M, Tsurui T, Iriguchi N, Ishiguro T, Hirasawa Y, Ariizumi H, Kubota Y, Horiike A, Yoshimura K, Wada S, Yamochi T, Tsunoda T. Suzuki R, et al. Among authors: iriguchi n. Front Oncol. 2023 Jul 10;13:1231986. doi: 10.3389/fonc.2023.1231986. eCollection 2023. Front Oncol. 2023. PMID: 37496666 Free PMC article.
Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy.
Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Sasaki Y, Homma M, Yamochi T, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: iriguchi n. Oncol Lett. 2023 Jul 20;26(3):381. doi: 10.3892/ol.2023.13967. eCollection 2023 Sep. Oncol Lett. 2023. PMID: 37559573 Free PMC article.
Novel quantitative immunohistochemical analysis for evaluating PD-L1 expression with phosphor-integrated dots for predicting the efficacy of patients with cancer treated with immune checkpoint inhibitors.
Ohkuma R, Miura S, Muto S, Toyomasu Y, Fujimoto Y, Ieguchi K, Onishi N, Shimizu T, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, Shimokawa M, Hirasawa Y, Ishiguro T, Suzuki R, Iriguchi N, Tsurui T, Mura E, Takenoshita S, Numajiri K, Okabe N, Yoshimura K, Tsuji M, Kiuchi Y, Yajima T, Ishida H, Suzuki H, Yamochi T, Kobayashi S, Tsunoda T, Wada S. Ohkuma R, et al. Among authors: iriguchi n. Front Immunol. 2023 Sep 18;14:1260492. doi: 10.3389/fimmu.2023.1260492. eCollection 2023. Front Immunol. 2023. PMID: 37790929 Free PMC article.
Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model.
Goshima T, Ieguchi K, Onishi N, Shimizu T, Takayanagi D, Watanabe M, Fujimoto Y, Ohkuma R, Suzuki R, Tsurui T, Mura E, Iriguchi N, Ishiguro T, Shimokawa M, Hirasawa Y, Kubota Y, Ariizumi H, Horiike A, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Fujishiro J, Hoffman RM, Tsunoda T, Wada S. Goshima T, et al. Among authors: iriguchi n. Anticancer Res. 2024 Jan;44(1):23-29. doi: 10.21873/anticanres.16784. Anticancer Res. 2024. PMID: 38159965
Chemotherapy combined with immune checkpoint inhibitors may overcome the detrimental effect of high neutrophil-to-lymphocyte ratio prior to treatment in esophageal cancer patients.
Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, Ishiguro T, Ohkuma R, Shimokawa M, Ariizumi H, Horiike A, Wada S, Yamashita T, Ariyoshi T, Goto S, Otsuka K, Murakami M, Kiuchi Y, Yoshimura K, Tsunoda T. Hirasawa Y, et al. Among authors: iriguchi n. Front Oncol. 2024 Oct 11;14:1449941. doi: 10.3389/fonc.2024.1449941. eCollection 2024. Front Oncol. 2024. PMID: 39464714 Free PMC article.
Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors.
Ishiguro T, Takeda K, Takayanagi D, Mura E, Suzuki R, Tsurui T, Iriguchi N, Hirasawa Y, Ohkuma R, Shimokawa M, Ariizumi H, Kubota Y, Horiike A, Izumizaki M, Wada S, Yoshimura K, Hoffman RM, Tsunoda T. Ishiguro T, et al. Among authors: iriguchi n. Cancer Genomics Proteomics. 2025 Jan-Feb;22(1):1-12. doi: 10.21873/cgp.20481. Cancer Genomics Proteomics. 2025. PMID: 39730175
13C MR imaging of methionine-rich gliomas at 4.7T: a pilot study.
Sasao A, Hirai T, Iriguchi N, Nakamura H, Kudo M, Sasao A, Yamashita Y. Sasao A, et al. Among authors: iriguchi n. Magn Reson Med Sci. 2011;10(2):139-42. doi: 10.2463/mrms.10.139. Magn Reson Med Sci. 2011. PMID: 21720117 Free article.
31 results